Learning Objectives
- Select the appropriate ADT modality (injectable vs. oral) based on patient-specific characteristics including adherence risk, planned treatment duration, cardiovascular profile, and drug-drug interaction preferences.
- Recognize the real-world implications of non-adherence on testosterone suppression and apply monitoring strategies to detect and manage suboptimal castration.
- Evaluate the role of longer-duration injectable ADT depots across short-course, radiotherapy-associated, and long-term ADT settings.
- Debate ADT switching in prostate cancer, anchored in clinical experience with injectable GnRH agonist therapy.
Videos
Podcasts
This program has been made possible through unrestricted support from TerSera.